Abstract

BackgroundDiabetes mellitus (DM) is an incurable metabolic disease constituting a major threat to human health. Insulin-producing cells (IPCs) differentiated from mesenchymal stem cells (MSCs) hold great promise in the treatment of DM. The development of an efficient IPC induction system is a crucial step for the clinical application of IPCs for DM. Laminin 411 is a key component of the basement membrane and is involved in the regulation of cell differentiation; however, little is known about a role of laminin 411 in the regulation of IPC differentiation from human MSCs.MethodsMSCs were isolated from human umbilical cord (UC-MSCs) and expanded in an in vitro culture system. UC-MSCs were then cultured in the IPC induction and differentiation medium in the presence of laminin 411. Flow cytometry, Quantitative realtime PCR, immunofluorescence staining, ELISA, Western blotting and other techniques were applied to determine IPC generation, insulin expression and related mechanisms. To evaluate potential therapeutic efficacy of IPCs induced from UC-MSCs, a type-1 diabetes (T1DM) rat model was generated using streptozotocin. Blood glucose, insulin levels, and survival of rats were monitored periodically following intravenous injection of the tested cells.ResultsLaminin 411 markedly induced the expression of the genes Foxa2 and Sox17, markers for pancreatic precursor cells, efficiently induced IPC differentiation from MSCs, and up-regulated insulin expression at both mRNA and protein levels. Furthermore, the expression of the genes known to govern insulin expression including Pdx1 and Ngn3 was markedly induced by laminin 411, which suggests that Pdx1 and Ngn3 signaling pathways are involved in laminin 411 induced-insulin expression machinery. More importantly, administration of laminin 411-induced IPCs rapidly and significantly down-regulated fasting blood glucose levels, significantly reduced the HbA1c concentration and markedly improved the symptoms and survival of T1DM rats.ConclusionsOur results demonstrate that laminin 411 acts as a potent differentiation inducer of IPCs from UC-MSCs via the Pdx1 and Ngn3 signaling pathways. Moreover, transfusion of laminin 411 induced-IPCs more efficiently improves symptoms and survival of T1DM rats. These novel finding highlights a potential clinical application of laminin 411 induced-IPCs in the treatment of T1DM, which calls for further studies.

Highlights

  • Diabetes mellitus (DM) is a group of metabolic disorders of carbohydrate metabolism, which constitutes a major threat to human health worldwide, in industrialized countries

  • Our results demonstrated that the laminin 411-based protocol significantly enhanced the induction of Insulin producing cells (IPC) differentiation from umbilical cord (UC)-Mesenchymal stem cells (MSC), and these IPCs produced significantly higher levels of insulin than those without laminin 411

  • umbilical cord Wharton’s jelly derived MSCs (UC-MSC) were subjected to conditions known to induce differentiation into bone, cartilage, and adipose cells

Read more

Summary

Introduction

Diabetes mellitus (DM) is a group of metabolic disorders of carbohydrate metabolism, which constitutes a major threat to human health worldwide, in industrialized countries. Classical treatments of DM consist of insulin injection and orally taking hypoglycemic drugs. Such daily therapeutic approaches markedly affect life quality of DM patients due to side-effects of the hypoglycemic drugs and suffering of injection. Novel treatments with long-lasting efficacy and lower side-effects are urgently needed. Developing alternative cellular therapy strategies for DM is an urgent task. Diabetes mellitus (DM) is an incurable metabolic disease constituting a major threat to human health. Insulin-producing cells (IPCs) differentiated from mesenchymal stem cells (MSCs) hold great promise in the treatment of DM. Laminin 411 is a key component of the basement membrane and is involved in the regulation of cell differentiation; little is known about a role of laminin 411 in the regulation of IPC differentiation from human MSCs

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.